Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovita Biological Technology Co (SHSE:688253) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Innovita Biological Technology Co EBITDA Margin % Related Terms
Innovita Biological Technology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovita Biological Technology Co EBITDA Margin % Chart
SHSE:688253 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Innovita Biological Technology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovita Biological Technology Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovita Biological Technology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Innovita Biological Technology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovita Biological Technology Co (SHSE:688253) has a EBITDA Margin % of 42.33% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Innovita Biological Technology Co and its competitors. This is near median its historical median of 45.21. Over the past decade, Innovita Biological Technology Co's EBITDA Margin % has ranged from 21.19 to 65.58. According to the industry distribution chart, Innovita Biological Technology Co ranks #113 out of 939 companies in the Biotechnology industry, placing it in the top 12%.
Is Innovita Biological Technology Co's EBITDA Margin % too high?
Innovita Biological Technology Co's current EBITDA Margin % of 42.33% is near median its 10-year median of 45.21. Over the past 10 years, this metric has ranged from a low of 21.19 to a high of 65.58. Based on the distribution chart, Innovita Biological Technology Co ranks #113 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Innovita Biological Technology Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innovita Biological Technology Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovita Biological Technology Co ranks #113 out of 939 companies for EBITDA Margin %. This places Innovita Biological Technology Co in the top 12% of its industry — outperforming the majority of peers. Historically, Innovita Biological Technology Co's own EBITDA Margin % has ranged from 21.19 to 65.58 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Innovita Biological Technology Co and its competitors. Innovita Biological Technology Co's current EBITDA Margin % is 42.33%, which is near median its own 10-year median of 45.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovita Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Innovita Biological Technology Co (SHSE:688253) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥20.48, compared to a current price of ¥58.92 — trading 187.7% above its estimated fair value. The current EBITDA Margin % is 42.33%, which is near median its 10-year median of 45.21. Innovita Biological Technology Co's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Innovita Biological Technology Co (SHSE:688253), the current EBITDA Margin % is 42.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovita Biological Technology Co (SHSE:688253) Overvalued in 2026?
Based on GuruFocus' analysis, Innovita Biological Technology Co stock appears to be overvalued.
The current stock price of ¥58.92 is trading 187.7% above its estimated GF Value™ of ¥20.48.
GuruFocus considers Innovita Biological Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:688253:
EBITDA Margin %: 42.33% (near median its 10-year median of 45.21)
GF Value™: ¥20.48 vs. price of ¥58.92 (187.7% above fair value)
No single metric tells the full story. See the SHSE:688253 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovita Biological Technology Co Business Description
Innovita Biological Technology Co Ltd is a biotechnology company focusing on the research and development, production, and sales of POCT in vitro diagnostic products.
61GF Score
Get the complete analysis for SHSE:688253
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688253 has been successfully added to your 
